Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis

NCT02704403 is registered in ClinicalTrials.gov with Genfit as lead sponsor.

NCT NCT02704403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02704403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis
Lead sponsor
Genfit
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2016
Completion date
October 28, 2020
Enrollment
2,157 (actual)
Sites
326

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis (nash) with fibrosis